comparemela.com

Latest Breaking News On - Bristol myers squibb opdivo - Page 16 : comparemela.com

Ikena Oncology, Vall d Hebron Institute Partner on Biomarker Research

The research on resistance mechanisms and drug combinations could aid the development of Ikena's drugs targeting the Hippo and RAS pathways.

United statesIsrael generalComunidad autonoma de catalunaMerck keytrudaBristol myers squibb opdivoJeffrey ecsedyJosep taberneroHebron institute of oncologyIkena oncologyHebron instituteBristol myers squibb

FDA rejects two China-developed cancer drugs

BioPharma

Innovent biologicsBristol myers squibb opdivoJunshi biosciencesVertex pharmaceuticalsDrug administrationMerck coKong based hutchmedShanghai based junshi biosciencesChina based innovent biologicsBristol myers squibbClinical trials

PureTech Announces Annual Results for Year Ended December 31, 2021

PureTech Announces Annual Results for Year Ended December 31, 2021 - read this article along with other careers information, tips and advice on BioSpace

New yorkUnited statesHong kongUnited kingdomCity ofSan franciscoUniversity of southern californiaBill bradfordAli bauerleinToby maherMichael davinVincent cottinEli lillyBharatt chowriraSimona leviTom wiggans

BeiGene Updates Phase III Data, Biomarker Analysis for Anti-PD-1 Drug in Nasopharyngeal Cancer

The analysis suggests tislelizumab plus chemo may be a first-line option for advanced patients, with a certain biomarker subgroup deriving the greatest benefit.

Li zhangUnited statesRobert haddadJunshi bioscienceMerck keytrudaBristol myers squibb opdivoAmerican society of clinical oncology plenary seriesDrug administrationSun yat sen university cancer centerOncology congressEuropean society for medical oncology immunoOncology panelDana farber cancer instituteNational comprehensive cancer networkAmerican societyClinical oncology plenary series

A promising cancer drug leads Regeneron to reconsider its aversion to M&A

BioPharma

Leonard schleiferBristol myers squibb opdivoAlnylam pharmaceuticalsMerck coDive briefCheckmate pharmaceuticalArt kriegBristol myers squibbIntellia therapeutics

vimarsana © 2020. All Rights Reserved.